Guggenheim Initiates HWM at Buy Amid 21% Monthly Pullback

Positioning in the lending market tells a completely different story from the analyst desk. Short interest, though rising, remains modest — 2.2% of the free float, up 12% on the week and 35% over the past month. That 35% build is worth noting: it has been a steady accumulation since mid-August, taking short shares from roughly 6.9 million to 8.9 million. That said, the absolute level stays low enough that this looks more like opportunistic shorts chasing a falling stock than a conviction-driven bear thesis building. Borrow conditions offer no encouragement to aggressive shorts: availability is enormous, with roughly 378 million shares available in the lending pool against 8.9 million borrowed — availability is at its maximum ceiling reading. Cost to borrow is 0.29%, effectively free money to hold a short. There is no squeeze pressure here whatsoever.

Options positioning has turned more defensive than it was earlier in the year, but not dramatically so. The put/call ratio is running at 1.23, slightly above its 20-day average of 1.20 — a z-score of just 0.15, well within normal range. Stepping back through the history, the PCR was sub-0.90 in mid-August when the stock was presumably stronger; it has drifted higher since. This is cautious hedging, not a crowded protective trade. The 52-week PCR range spans 0.67 to 1.57, so current readings sit comfortably in the middle.

The August 6 earnings print is the most recent data point the market is still processing. The stock fell 3.3% on the day and extended losses to nearly 3% over the following week — a modest but negative reaction to what was presumably a solid-enough report given the wave of target upgrades that followed. The next event is November 6. With the stock now down 21% from its recent peak and sitting well below analyst targets, that print carries additional weight: the question will be whether management reiterates the demand outlook that justified $350 targets, or signals any softness in its aerospace engine components order book.

The insider register adds a cautionary note. EVP and CAO Neil Marchuk sold $11.3 million of stock in May at around $269 — a discretionary open-market sale, not a 10b5-1 plan, at prices 17% above where the stock trades now. No material open-market buying has appeared since. The institutional base remains stable and concentrated in passive names: BlackRock holds 11.5% and Vanguard entities together account for a further 12%. No activist has filed a Schedule 13D; the 13G register reflects passive accumulation only.

What to watch next: whether short interest continues its month-long build toward 3% of float as the stock stabilises, and whether any of the 16 Buy-rated analysts revisit their targets or conviction ahead of the November earnings call.